Gregory Kalemkerian
Professor of Internal Medicine
Associate Division Chief for Faculty Development & Education
Internal Medicine - Hematology/Oncology
1500 E. Medical Center Drive
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
Gregory Kalemkerian
Clinical Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Proceeding / Abstract / Poster
      A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
      Qin A, Wells L, Malhotra B, Gadgeel S, Schneider BJ, Ramnath N, Rice JD, Kalemkerian GP. Clin Lung Cancer, 2024 Mar; 25 (2): 128 - 134. DOI:10.1016/j.cllc.2023.10.011
      PMID: 37977950
    • Journal Article
      Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
      Griesinger F, Curigliano G, Subbiah V, Baik CS, Tan DS, Lee DH, Misch D, Garralda E, Kim D-W, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Future Oncol, 2024 Feb; 20 (6): 297 - 306. DOI:10.2217/fon-2023-0155
      PMID: 37916501
    • Journal Article
      Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.
      Khurshid H, Ismaila N, Bian J, Dabney R, Das M, Ellis P, Feldman J, Hann C, Kulkarni S, Laskin J, Manochakian R, Mishra DR, Preeshagul I, Reddy P, Saxena A, Weinberg F, Kalemkerian GP. J Clin Oncol, 2023 Dec 10; 41 (35): 5448 - 5472. DOI:10.1200/JCO.23.01435
      PMID: 37820295
    • Journal Article
      Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
      Kim HR, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC-H, Mazieres J, Orlandi FJ, Luft A, Gümüş M, Kato T, Kalemkerian GP, Luo Y, Santorelli ML, Pietanza MC, Rudin CM. JTO Clin Res Rep, 2023 Nov; 4 (11): 100572 DOI:10.1016/j.jtocrr.2023.100572
      PMID: 37954964
    • Journal Article
      Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).
      Wozniak AJ, Schneider B, Kalemkerian GP, Daly B, Chen W, Ventimiglia J, Nagasaka M, Zauderer MG. Clin Lung Cancer, 2023 Sep; 24 (6): 563 - 567. DOI:10.1016/j.cllc.2023.04.004
      PMID: 37301693
    • Journal Article
      Lung Cancer in Armenia.
      Zohrabyan D, Karapetyan N, Danielyan S, Saghatelyan T, Safaryan L, Bardakhchyan S, Tamamyan G, Harutyunyan M, Rushanyan M, Mkrtchyan G, Badalyan S, Avagyan A, Harutyunyan L, Lazaryan A, Mkhitaryan S, Khanoyan A, Sargsyan A, Mailyan M, Mamunts D, Asadyan A, Khachatryan P, Mkhitaryan A, Kalemkerian GP. J Thorac Oncol, 2023 Apr; 18 (4): 402 - 409. DOI:10.1016/j.jtho.2022.12.015
      PMID: 36990573
    • Chapter
      Non-Small Cell Lung Cancer: Stages II and III
      Kalemkerian GP, Sankar K, Qin A. 2023 Jan 1; 1: Cancer Consult: Expertise in Clinical Practice, Volume 1: Solid Tumors and Supportive Care, 63 - 77. DOI:10.1002/9781119823766.ch6
    • Journal Article
      Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
      Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim D-W, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Ann Oncol, 2022 Nov; 33 (11): 1168 - 1178. DOI:10.1016/j.annonc.2022.08.002
      PMID: 35973665